Literature DB >> 28715281

Admission for COPD Exacerbation Is Associated with the Clinical Diagnosis of Pulmonary Hypertension: Results from a Retrospective Longitudinal Study of a Veteran Population.

Sarah K Medrek1, Amir Sharafkhaneh1,2, Andrew M Spiegelman3, Arnav Kak4, Lavannya M Pandit1,2.   

Abstract

Patients with chronic obstructive pulmonary disease and pulmonary hypertension (PH-COPD) have an increased risk of hospitalizations and death compared to COPD alone. Identifying PH in COPD is challenging because performing right heart catheterization, the gold standard for PH diagnosis, is invasive and not routinely performed. Clinical characterization of COPD patients at risk who are progressing toward PH will aid therapeutic development at earlier stages of progressively fatal PH-COPD. We studied the records of 5,45,086 patients in a large Veterans Affairs healthcare network (2000-2012) with a primary discharge diagnosis of COPD based on encounters' ICD-9 codes and further stratified into those who received an additional ICD-9 code for a PH diagnosis. Patients with PH-COPD were assigned to one of the four subgroups: those with (a) no history of exacerbation or hospital admissions, (b) history of exacerbations but no hospital admissions, (c) hospital admissions unrelated to COPD and (d) history of COPD exacerbation-related hospital admissions. We also examined the COPD and COPD-PH cohorts for associated comorbidities such as cardiac disease and the presence of obstructive sleep apnea (OSA). A regression analysis revealed that patients with COPD exacerbation-related hospital admissions had 7 × higher risk of having a concomitant clinical diagnosis of PH compared to non-hospitalized patients. COPD-PH patients had higher rates of cardiac comorbidities (89% vs. 66%) and OSA (34% vs. 16%) compared to COPD alone. We conclude that COPD patients hospitalized for COPD exacerbations are at a higher risk for developing PH, and hospitalized COPD patients with cardiac comorbidities and/or OSA should be screened as at-risk population for developing PH.

Entities:  

Keywords:  Chronic obstructive pulmonary disease; pulmonary hypertension

Mesh:

Year:  2017        PMID: 28715281     DOI: 10.1080/15412555.2017.1336209

Source DB:  PubMed          Journal:  COPD        ISSN: 1541-2563            Impact factor:   2.409


  14 in total

1.  A Nomogram for Predicting the Risk of Pulmonary Hypertension for Patients with Chronic Obstructive Pulmonary Disease.

Authors:  Ning Wang; Zhenjiang Guo; Xiaowei Gong; Shiwei Kang; Zhaobo Cui; Yadong Yuan
Journal:  Int J Gen Med       Date:  2022-06-22

2.  Diffusing Capacity Is an Independent Predictor of Outcomes in Pulmonary Hypertension Associated With COPD.

Authors:  Aparna Balasubramanian; Todd M Kolb; Rachel L Damico; Paul M Hassoun; Meredith C McCormack; Stephen C Mathai
Journal:  Chest       Date:  2020-03-14       Impact factor: 9.410

Review 3.  Pulmonary Arterial Hypertension: a Pharmacotherapeutic Update.

Authors:  James C Coons; Kristen Pogue; Andrew R Kolodziej; Glenn A Hirsch; Marjorie Patricia George
Journal:  Curr Cardiol Rep       Date:  2019-11-22       Impact factor: 2.931

4.  Body habitus in patients with and without bronchiectasis and non-tuberculous mycobacteria.

Authors:  Michael D Schweitzer; Oriana Salamo; Michael Campos; Dean E Schraufnagel; Ruxana Sadikot; Mehdi Mirsaeidi
Journal:  PLoS One       Date:  2017-09-28       Impact factor: 3.240

Review 5.  Updated Perspectives on Pulmonary Hypertension in COPD.

Authors:  Isabel Blanco; Olga Tura-Ceide; Victor Ivo Peinado; Joan Albert Barberà
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2020-06-09

6.  Pulmonary hypertension in chronic lung disease and hypoxia.

Authors:  Steven D Nathan; Joan A Barbera; Sean P Gaine; Sergio Harari; Fernando J Martinez; Horst Olschewski; Karen M Olsson; Andrew J Peacock; Joanna Pepke-Zaba; Steeve Provencher; Norbert Weissmann; Werner Seeger
Journal:  Eur Respir J       Date:  2019-01-24       Impact factor: 16.671

7.  Parenteral prostanoids for severe Group 3 pulmonary hypertension with right ventricular dysfunction.

Authors:  Colin A Hinkamp; Trushil Shah; Sonja Bartolome; Fernando Torres; Kelly M Chin
Journal:  J Thorac Dis       Date:  2021-03       Impact factor: 2.895

8.  Accuracy of echocardiography and chest tomography for pulmonary hypertension screening in patients awaiting lung transplantation.

Authors:  Luiza Helena Degani-Costa; João Paulo de Assis; Pedro Paulo Pisaniello Gonçalves; Fernanda Gushken; Gilberto Szarf; José Eduardo Afonso Junior
Journal:  Einstein (Sao Paulo)       Date:  2021-12-20

Review 9.  Diagnosis and Management of Pulmonary Hypertension in the Modern Era: Insights from the 6th World Symposium.

Authors:  Christopher A Thomas; Ryan J Anderson; David F Condon; Vinicio A de Jesus Perez
Journal:  Pulm Ther       Date:  2019-11-29

10.  Clinical impact of pulmonary hypertension on the outcomes of acute myocardial infarction patients with or without chronic obstructive pulmonary disease.

Authors:  Seok Oh; Ju Han Kim; Kyung Hoon Cho; Min Chul Kim; Doo Sun Sim; Young Joon Hong; Youngkeun Ahn; Myung Ho Jeong
Journal:  Medicine (Baltimore)       Date:  2022-01-21       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.